Charles River Associates (CRAI)
(Delayed Data from NSDQ)
$163.48 USD
+3.06 (1.91%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $162.92 -0.56 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.48 USD
+3.06 (1.91%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $162.92 -0.56 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Zacks News
Wall Street Cheers Soft Inflation Data: 5 Growth Picks
by Tirthankar Chakraborty
Invest in growth stocks like Murphy USA (MUSA), Merck (MRK) & New Fortress Energy (NFE), to name a few, as Wall Street rises on signs of cooling inflation.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CRA (CRAI) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CRA (CRAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Cross Country Healthcare (CCRN) Outperforming Other Business Services Stocks This Year?
by Zacks Equity Research
Here is how Cross Country Healthcare (CCRN) and CRA International (CRAI) have performed compared to their sector so far this year.
Best Income Stocks to Buy for November 9th
by Zacks Equity Research
RDN, ENLC and CRAI made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 9, 2022.
New Strong Buy Stocks for November 9th
by Zacks Equity Research
ENLC, TITN, CRAI, FIX and MTG have been added to the Zacks Rank #1 (Strong Buy) List on November 9, 2022.
Best Value Stocks to Buy for November 9th
by Zacks Equity Research
CASH, MTG and CRAI made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 9, 2022.
Best Growth Stocks to Buy for November 9th
by Zacks Equity Research
DINO, HEES and CRAI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 9, 2022.
Charles River Associates (CRAI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CRA (CRAI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CRA International (CRAI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
CRA (CRAI) delivered earnings and revenue surprises of 33.33% and 0.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gartner (IT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gartner (IT) delivered earnings and revenue surprises of 30.27% and 4.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CBIZ (CBZ) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CBIZ (CBZ) delivered earnings and revenue surprises of 10.87% and 8.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Business Services Stocks Lagging Charles River Associates (CRAI) This Year?
by Zacks Equity Research
Here is how CRA International (CRAI) and Cross Country Healthcare (CCRN) have performed compared to their sector so far this year.
Here's Why Investors Should Retain ADP Stock in Portfolio Now
by Zacks Equity Research
Strong business model, high recurring revenues and good margins boost ADP.
Here's Why Investors Should Retain Xerox (XRX) Stock Now
by Zacks Equity Research
Ongoing investments and recurring revenues boost Xerox (XRX).
CRAI or FC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CRAI vs. FC: Which Stock Is the Better Value Option?
Here's Why Investors Should Retain Trane Technologies (TT) Now
by Zacks Equity Research
Focus on growth objectives and pro-investor steps boost Trane Technologies (TT).
Here's Why Investors Should Retain Maximus (MMS) Stock Now
by Zacks Equity Research
Solid track record of dividend payments boosts Maximus (MMS).
Here's Why H&R Block (HRB) Stock Gained 70.3% in the Past Year
by Zacks Equity Research
Five-year strategy plan and investor-friendly moves boost H&R Block's (HRB) shares.
Reasons to Hold Broadridge (BR) Stock in Your Portfolio
by Zacks Equity Research
Broadridgen's (BR) business is currently benefiting from strong growth in equity and fund records, and the transformation and digitization of the financial services industry.
Here's Why Genpact (G) Gained 4.9% in the Past 3 Months
by Zacks Equity Research
Customer acquisitions and investor-friendly moves boost Genpact's (G) shares.
Charles River (CRAI) Rides on Global Presence & Diversification
by Zacks Equity Research
Charles River (CRAI) is currently benefiting from its diversified business as well as shareholder-friendly steps.
Gartner (IT) Gains 14% in the Past 3 Months: Here's How
by Zacks Equity Research
Gartner (IT) has a large and diverse addressable market with low customer concentration that mitigates operating risks.
Why Investors Should Retain FTI Consulting (FCN) Stock Now
by Zacks Equity Research
FTI Consulting (FCN) has a steady track record of share repurchases.
Reasons to Retain TransUnion (TRU) Stock in Your Portfolio
by Zacks Equity Research
TransUnion's (TRU) gigantic treasure trove of data is its most distinguishing asset and also perhaps the biggest barrier to entry for competitors.